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1. Introduction 
Human Thyroid Tumors represent a multistage model of epithelial tumorigenesis. Even 
though a majority of these tumors originate from follicular cells, they exhibit a broad 
spectrum with different phenotypic characteristics and variable clinical behavior. Our recent 
studies suggest that numerous growth factors and their receptors may be abnormally 
overexpressed or constitutively activated in thyroid tumors to influence their biological 
behavior. In this chapter we review our current understanding of the role of Insulin-like 
growth factors (IGFs) and their receptors in the pathogenesis of thyroid cancer and how 
expression of pIGF-IR may be an indicator of their clinical behavior [1]. Mechanistic 
evidence for direct involvement of IGF-I signaling in metastasis of anaplastic thyroid cancer 
& on tumor associated angiogenesis [2] is also discussed. Finally, as several small molecular 
inhibitors of IGF-IR signaling (peptide-based antagonists and monoclonal antibodies) are 
being tested, we will discuss the potential impact of utilizing IGF-I signaling pathway as a 
therapeutic target [2, 3] for aggressive thyroid cancers especially in cases where the current 
therapeutics have failed to show a favorable outcome. 
Thyroid cancer (TC) is one of the most common endocrine malignancies worldwide. 
According to recent American Cancer Society (ACS) estimates, its incidence is rising in the 
US, with an average increase of 6% between 1975 & 2008[4]. Recent data further indicates 
that its incidence is three times higher in women than in men amongst all ethnic 
populations. Even though a majority of these tumors originate from follicular cells, they 
exhibit a broad spectrum with different phenotypic characteristics and variable clinical 
outcomes. Histopathological evaluation of TC specimens suggests that these tumors can be 
further sub-classified as differentiated thyroid carcinoma (DTC), undifferentiated 
(anaplastic) thyroid carcinoma (ATC) and medullary thyroid carcinoma (MTC). DTC and 
ATC are also referred to as nonmedullary thyroid cancer (NMTC) and may include 
subtypes like Hurthle cell carcinomas (HCC). Ninety to ninety three percent of all thyroid 
tumors are of differentiated phenotypes and have a papillary (PTC) or follicular (FTC) 
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morphology. Usually these tumors follow a protracted clinical course with a 10-year survival 
rate of 92%. Another 5% are MTCs where the 5-year survival rate is approximately 50%. On 
the contrary, ATCs arise either de novo or may evolve from follicular or papillary carcinomas. 
These tumors are rare, occurring in only 1-2% of all TCs, and are invariably associated with 
fatal outcomes [5]. In the clinic, these patients present themselves with widely invasive local 
disease and are surgically incurable. The survival rate for ATCs which frequently metastasize 
to distant sites, is <10%. Severity of ATC is further underscored by the fact that even when 
these patients receive aggressive multimodal therapy such surgery, radiotherapy, and 
chemotherapy, more than 80% of patients die within months, especially those who are more 
than sixty years of age[6]. An in-depth understanding of thyroid cancer biology is therefore a 
necessary prerequisite to develop better management schemes for different types of thyroid 
cancers. Furthermore, the information gleaned could be utilized to make therapeutic advances 
that may improve the outcomes of thyroid cancer patients in the near future.  
So far, study of genetic and epigenetic alterations in thyroid cancer cells has given us 
exciting new insights into the mechanisms that give rise to thyroid tumors [7]. Even though  
 
Table 1. Single and multi-kinase inhibitors under clinical development for treating thyroid 
cancer. 
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we may be far away from a clear understanding of the complete set of molecular events that 
transform benign thyroid cells into tumorigenic cells, a vast majority of literature indicates 
that signals originating from growth factors (GF) and their receptors play an important role 
in fueling the growth of aggressive cancer.  
It is well established that GF signaling is required for maintaining the malignant phenotype 
through alteration of the cell cycle, induction of apoptosis, and modulation of the behaviour 
of tumor cell or its micro-environment [8]. It is no surprise then that GF and their receptors 
have become attractive candidates for targeted therapy of cancer[9]. Constitutive signaling 
through the receptor tyrosine kinases (RTKs), particularly the epidermal growth factor 
receptor (EGFR, erbB1), Her2/neu (c-erbB2), and vascular endothelial growth factor  
receptor (VEGFR) has been reported in multiple tumor types including TC. This has opened 
up the possibility of blocking them with small molecule tyrosine kinase inhibitors (TKIs) 
either as single agent or as a cocktail of multi-kinase complexes (see Table 1), or with human 
or humanized monoclonal antibodies (mAb) (see Table 2). 
 
Table 2. Monoclonal antibodies as inhibitors of receptor tyrosine kinases. 
Insulin-like growth factor–I receptor (IGF-IR) is another candidate gene that has gained 
popularity as a viable RTK target in the last two decades for several different reasons [10, 
11]. The most significant reason is that multiple oncogenes require the presence of IGF-IR 
to achieve cellular transformation[12]. In addition, IGF-I signaling confers resistance to 
many therapies that currently constitute the standard of care in oncology[13-15]. 
Furthermore, epidemiological studies have shown that elevated plasma levels of IGF-I are 
associated with higher risk of several cancers (breast, colon, prostate and lung) [16-19]. All 
of these data suggest that instead of using conventional cytotoxic chemotherapy, targeting 
the IGF-I axis may be an important, effective and well-tolerated therapeutic alternative for 
treating cancer[20]. Indeed, several anti-IGF-IR compounds are in Phase I and Phase II 
clinical trials[21] to measure their anti-tumor effects as single agents or when given in 
combination with chemotherapy or radiotherapy (Table 3). However, very few studies 
have looked at the role of IGF-IR signaling in TC or evaluated the potential of anti-IGF-IR 
therapy for in this cancer. We investigated whether enhanced IGF-IR signaling promotes  
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Table 3. Drugs targeting Type I insulin-like growth factor receptor.  
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thyroid cancer progression and if so, is it a viable candidate for RTK therapy in thyroid 
cancer. In this chapter, we review the basics of IGF-IR signaling, our experience with over-
expression of IGF-IR signaling components in TC and how blockade of IGF-I signaling 
through its receptor has the potential to curb the growth of poorly differentiated FTC and 
ATC. Later sections of the chapter also describe important molecular changes resulting from 
IGF-IR blockade and their influence on tumor growth. 
2. Brief overview of insulin-like growth factor receptor signaling  
Major components of IGF signaling axis include the three ligands (IGF-I, IGF-II & Insulin), 
IGF binding proteins (IGFBPs) and the three tyrosine kinase receptors, namely, IGF-IR, IGF-
IIR and Insulin receptor (IR). All of these ligands can act as circulating hormone or tissue 
growth factors. Similarly, the IGFBPs are also produced in the liver or other organs and  
 
Fig. 1. Schematic of Insulin like growth factor receptor illustrating its different domains and 
the position of sulphide bonds. IGF-IR is a trans-membrane tyrosine kinase and consists of 
two ┙┚ chains and has high affinity for its ligands IGF-I and IGF-II. Insulin can also bind 
and signal through this receptor although with much lower affinity. 
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delivered to the target tissue in an endocrine manner. The balance of IGF-I, either bound to 
IGFBP or its unbound form determine whether a cell will follow a survival pathway or follow 
an apoptotic course. Free IGF-I exerts its effects through the activation of IGF-IR, its preferred 
cell surface receptor. IGF-IR is synthesized as a precursor peptide of 1367 amino acid residues. 
It is then cleaved at residue 706, to dissociate the  chain containing the extracellular domain 
from the ┚-chain that encompasses the transmembrane and tyrosine kinase domains (Fig. 1). 
It moves to the membrane fully assembled in the dimeric form with two ┙-chains and two ┚-
subunits[22]. Signaling through IGF-IR is initiated when IGF-I and IGF-II produced by the 
liver and at many extra hepatic sites including tumor cells and stromal fibroblasts or insulin 
bind to IGF-IR. Upon ligand binding, IGF-IR is auto phosphorylated to stimulate its tyrosine 
kinase activity that subsequently phosphorylates additional intracellular substrates, 
including insulin receptor substrates-1 through 4 (IRS-1-4) and Shc (an SH2 domain 
containing adaptor protein). These early events activate multiple signaling pathways, 
including the mitogen-activated protein kinase [MAPK, extracellular signal-regulated kinase 
(ERK)] and phosphatidylinositide 3-kinase (PI3-K)/Akt-1 (protein kinase B) pathways (Fig. 
2)[23, 24]. Signaling from IGF-IR is known to play a crucial role in organ development[25-
27]during embryogenesis and regulation of mitogenesis through suppression of apoptosis 
and stimulation of proliferation[28]. 
 
Fig. 2. IGF-IR signaling and two most frequently used IGF-IR inhibition strategies: In 
response to ligand binding, IGF-IR┚ gets activated and phosphorylates adaptor proteins 
belonging to the IRS family or SHC. Activation of IRS and SHC leads to activation of 
extracellular signal–regulated kinase (ERK) 1/2 of the MAPK cascade via the growth factor 
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receptor binding protein 2 (Grb2)/Sos/Ras/Raf/MAPK extracellular signal–regulated 
kinase kinase (MEK) pathway. IRS proteins also bind to the p110 subunit of PI3K, leading to 
the generation of phosphatidylinositol 3,4.5-triphosphate (PIP3) and phosphorylation of Akt 
by phosphoinositide dependent kinase (PDK1). Phosphorylation of Akt leads to subsequent 
activation of mammalian target of rapamycin (mTOR), eukaryotic translation initiation 
factor 4E (eIF4E), and p70S6 kinase (S6K). Activation of these downstream signaling 
pathways leads to enhanced proliferation, survival, and metastasis in cancer cells. Similar 
signaling pathways are activated by IR and other IGF-IR/IR hybrid receptors.  
In normal cells, the IGF/IGF-IR signaling is regulated at multiple levels (Fig. 3)[29]. Initially, 
Growth hormone-releasing hormone (GHRH) stimulates the expression of growth hormone 
(GH) produced in the pituitary gland. GH then stimulates the secretion of IGFs and IGFBPs 
from the hepatocytes [30]. As stated earlier, activation of IGF-IR is tightly regulated by 
amount of free forms of the ligands, which is controlled by the action of IGFBP and the type 
2 IGF receptor (IGF-IIR) also known as mannose 6-phosphate receptor. This receptor can 
bind IGF-II but lacks tyrosine kinase activity. Accordingly, when IGF-II binds the receptor, it 
fails to transduce its signal and just serves as a sink for the IGF-II. This reduces the 
circulating levels of IGF-II thus enhancing the signalling of IGF-IR [31].  
 
Fig. 3. Growth hormone (GH) and Thyroid stimulating hormone (TSH) are produced under 
the influence of hypothalamic factors. GH controls the secretion of IGF-I, IGF-II and IGFBPs 
from liver, whereas TSH controls the secretion of T3 & T4 that regulate thyroid growth. In 
normal thyroid cells TSH cooperates with IGF-I signaling to promote thyroid growth and 
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function. However, in some cases, excessive constitutive synthesis of IGF-I may be involved 
in abnormal growth of the thyroid. 
In contrast, IGFBP 1-6 modulate IGF activity by reducing bioavailability of IGFs that may 
bind to the IGF-IR. The complex balance between the IGFs and the IGFBPs is modulated by 
specific IGFBP proteases, such as matrix metalloproteinase (MMP)[32]. Like IGF-I and IGF-
II, Insulin can also signal through the IGF-IR, IR and the IGF-IR/IR hybrid receptor to 
induce a variety of biological effects in typical insulin target (adipocyte, hepatocyte, and 
myocyte) cells[33] and in cancer cells. Upon ligand binding, insulin/IGF-IR undergoes auto-
phosphorylation on tyrosine residues, activating the same downstream signaling cascade as 
the ones initiated upon IGF-I binding. However, as insulin binds to the IGF-1R with 100- to 
1000-fold lower affinity than IGF-I[34], most of the signaling from the IGF-IR may be 
assumed to be the result of IGF-I signaling. Nevertheless, the high degree of homology of 
IGF-IR to insulin receptor has been a considerable challenge for the development of anti-
IGF-IR therapies that are specific to IGF-IR.  
3. Role of IGF-IR signaling axis components in human thyroid cancers 
Inappropriate IGF-IR signaling is implicated in the development and progression of several 
human malignancies [35] including those of the thyroid[36-38], and often correlates with 
poor prognosis[39, 40]. Activation of IGF-IR is essential for the mitogenic effects of TSH and 
for thyroid function [41-44]. Unlike other growth factor receptors, IGF-IR and insulin 
receptor (IR) are not inhibitory to thyroid function. Instead they cooperate with TSH to 
stimulate growth (Fig. 3). However, in some cases, excessive constitutive synthesis of IGF-I 
has been shown to be involved in abnormal growth of the thyroid[45]. Additional 
accumulated evidence from studies of other neoplasms suggests that in addition to the TSH-
IGF-I nexus, there are several other mechanisms by which IGF-IR signaling may be 
dysregulated in human tumors. It can be constitutively activated through autocrine or 
paracrine signaling[39, 46]. Alternatively, ligand-independent mechanisms can result in the 
activation of the receptor[47]. By far, the most common occurrence is overexpression of IGF-
IR. However, whether that is the case in thyroid cancer is unknown.  
4. IGF-I and IGF-IRß expression is high in all histological subtypes of thyroid 
cancer and thyroid cancer cell lines  
In recent studies, the authors measured the expression of IGF-I, IGF-IRß and 
phosphorylated IGF-IR┚ (pIGF-IR┚) in normal and neoplastic human thyroid tissue to 
determine whether IGF-I axis plays a role in thyroid tumor progression. Evaluation of the 
distribution and abundance of IGF-l in human thyroid cancers with different 
histopathologic characteristics showed that immunoreactive IGF-l was present in all the 
thyroid tissues examined. Its expression was lowest in normal the thyroid tissues and 
highest in all thyroid carcinomas studied. Examination of expression level of IGF-IR in 
normal and neoplastic thyroid tissue on human tissue arrays showed that none of the 
normal thyroid tissue specimens stained positively for IGF-IR, whereas 60 out of 63 
specimens of thyroid cancer were positive. The intensity of staining ranged from + to +++ 
(+ being low, ++ moderate and +++high). Compared to the normal thyroid tissue 
specimens, the positive staining rate of ATC (37/39, 94%) FTC (11/11, 100%) and PTC 
(12/13, 92%) specimens revealed statistically significant differences in IGF-IRß expression 
www.intechopen.com
Insulin-Like Growth Factor Receptor Signaling in Thyroid Cancers:  
Clinical Implications and Therapeutic Potential 
 
99 
(P < 0.001). No statistical differences between ATC, FTC-and PTC-positive staining (Fig. 
4A and Table 4) were noted.  
Similar analysis of the thyroid cancer cell lines confirmed our findings from human tumor 
specimens. As per our expectation, most of the FTC and PTC cell lines showed little 
variability in IGF-IR┚ expression. But its expression was comparatively lower in ATC cell 
lines. pIGF-IR┚ expression on the other hand was variable. Overall, FTC and PTC cell 
lines had higher pIGF-IR┚ levels compared to the normal thyroid cells or the anaplastic 
cell lines (Fig. 4B & C). It is important to mention here that the data presented is for 
representative cell lines only. More details can be accessed at Wang et.al. (2006)[2]. 
Nevertheless, despite the high IGF-IR content of several of the thyroid cancer cell lines 
tested, auto-phosphorylation of the receptor in response to IGF-I stimulation was 
observed only in cell lines that had an intact IGF-I axis. Evaluation of the phosphorylated 
form of the receptor (pIGF-IR) in surgical specimens of human FTC, PTC and ATC 
indicated that both FTC and PTC specimens had moderate to high levels of pIGF-IR. But 
neither the ATC specimens nor most of the ATC cell lines tested had detectable levels of 
pIGF-IR (Fig 4B). This data implied attenuated expression of growth-signaling 
components of the IGF system. In particular low pIGF-IR expression may be associated 
with malignant phenotype or more aggressive form of thyroid cancer. To test this 
hypothesis further, a quantitative immunohistochemical assay for pIGF-IR expression was 
developed[1] and archival human thyroid tumor microarrays containing specimens with 
10 to 12 year follow up were analyzed as described. 
 
Table 4. Level of immunohistochemical staining for IGF-IR┚ in normal thyroid, follicular, 
papillary and anaplastic thyroid cancer tissue from 63 human surgical samples  
(including specimens on tissue array and permanent pathological slides) [2]. 
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Fig. 4A. Expression of pIGF-IR┚ is down regulated in majority of anaplastic and some 
papillary thyroid cancer specimens: Immunoperoxidase staining of thyroid tumor tissue 
sections to visualize expression of endogenous IGF-I, IGF-IR┚ and pIGF-IR┚. The black 
boxed area indicates that as compared to normal thyroid tissue, PTC, FTC and ATC 
specimens show overexpression of IGF-IR┚, whereas expression of pIGF-IR┚ is down 
regulated in majority of ATC and PTC specimens. In contrast pIGFIR┚ expression 
(highlighted in red boxed specimen) is retained mostly in FTC specimens [1]. 
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Fig. 4B. & C. IGF-IR┚/IR┚ and pIGF-IR┚ expression in representative thyroid cancer cell 
lines detected immunochemically using Western blotting (B) and Immunofluorescence (C). 
Total IGF-IR┚ expression was detectable in all cell lines tested. pIGF-IR┚ expression varied 
amongst cell lines and was almost undetectable in ATC cell lines. Its expression was lower 
in normal thyroid (TAD2) cells compared to the FTC cell lines. C) Immuno-fluorescent 
detection of pIGF-IR┚ in FTC and ATC cell lines after stimulation with 10ng/ml IGF-I  
(top panels) or in serum free media (SFM). Green signal = pIGF-IR; Blue = DAPI. 
4.1 pIGF-IR expression is high in differentiated thyroid cancers but its expression is 
attenuated in more aggressive thyroid cancers  
Two thyroid tumor tissue arrays (TMA) containing 120 specimens on one and 84 specimens 
on the other, were analyzed in this study. One of the arrays also contained six pairs of 
normal thyroid tissue from the same patient. Detailed analysis of these tissue arrays (see 
Table 6 for demographics) confirmed that the pIGF-IR content of the differentiated 
component of the tumors was higher as compared to the matched pair of the normal tissue 
specimen. However, on the whole, all poorly differentiated tumor types, particularly the 
ATCs, showed negligible expression of pIGF-IR (Fig. 5). 
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Fig. 5. Immunohistochemical analysis of IGF-IR┚ and pIGF-IR┚/IR┚ in histological subtypes 
of thyroid carcinoma: A. Representative paraffin-embedded sections of normal and 
histologcal subtypes of thyroid carcinoma treated with the anti-IGF-IR┚ antibody (a – d) and 
anti-pIGF-IR┚/IR┚ Ab (e-h). Panels a & e are sections from normal thyroid tissue treated 
with the two antibodies mentioned above. Note that the normal tissue has very low levels of 
IGF-IR or pIGF-IR/IR as compared to the adjacent panels showing intense staining in tumor 
tissues. Additionally, only follicular thyroid carcinoma samples and few papillary 
carcinoma were more often positive for anti-pIGF-IR┚/IR┚ antibody staining even though 
all the tumor tissue types had detectable IGF-IR┚ expression. Scale bar represents 50µm [1]. 
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Fig. 6A. pIGF-IR┚/IR┚ index of thyroid cancer specimens: Frequency distribution of  
pIGF-IR/IR index in a total of 17 Anaplastic (a) and 47 Follicular (b) thyroid carcinoma 
cases. Overall, more FTC specimens demonstrated a higher pIGF-IR┚ index. 
This was further substantiated by histogram analysis of all the morphological histotypes of 
thyroid cancer, where 74% of ATC specimens showed a pIGF-IR index below 400 as 
opposed to only 34% of the FTC (Fig. 6A). Furthermore, a significant difference was noted in 
the median pIGF-IR index of different histological subtypes of thyroid cancer (P<0.001) (Fig. 
6A). When all thyroid cancers were stratified as differentiated [FTC, PTC and Hurthle cell 
carcinoma (HCC)] or other thyroid cancers (ATC and MTC), the median pIGF-IR index of 
differentiated thyroid cancer was significantly higher than the median index of other 
thyroid cancers (114 vs. 63, P<0.001, Fig. 6B).  
 
Fig. 6B. Median pIGF-IR┚/IR┚ index of differentiated thyroid carcinoma was significantly 
higher than that of all other thyroid cancers p<0.001 (Mann-Whitney test).  
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To make the predictive power of our analysis more significant, additional parameters such 
as age, tumor size, tumor grade and lymph node metastasis were analyzed along with the 
pIGF-IR index of the specimen.  
Our data showed that when patients with PTC or FTC were stratified according to their age, 
the mean pIGF-IR index of differentiated thyroid cancer patients above 45 years of age was 
significantly lower than the mean pIGF-IR index of patients below 45 years of age. However, 
due to the small sample size of our study, statistical significance couldn’t be reached, 
although, a clear trend was noted (Table 5A). No significant difference was noted in the 
pIGF-IR index of tumors grouped by size or stage. Furthermore, although lymph node (LN) 
metastasis is not a good prognostic indicator in thyroid cancer, it does indicate recurrence 
and local control. Accordingly, when tumors were stratified based on their LN status, our 
analysis indicated that patients with differentiated thyroid cancer without lymph node 
metastases have a significantly higher pIGF-IR index (P = 0.03) as compared to patients with 
lymph node metastasis. Once again, no significant difference was noted among those 
patients with poorly differentiated thyroid cancer with or without lymph node metastasis  
(P = 0.12) (Table 5B)[1].  
 
Table 5A. pIGF-IR┚/IR┚ index variability by age in differentiated thyroid cancers. 
 
Table 5B. pIGF-IR┚/IR┚ expression vs. patient outcome 
Overall, low pIGF-IR expression was found to correlate with aggressive human thyroid 
carcinoma. It is thus likely that IGF-IR signaling may not be needed for progression of ATC 
as other cell signaling pathways may be activated in these cells thereby obviating the need 
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for intact IGF-IR signaling. Nonetheless, as both IGF-IR┚ & pIGF-IR┚ were up-regulated in a 
majority of differentiated thyroid carcinomas, we hypothesized that IGF-IR may be a viable 
potential target for therapy in patients with more differentiated types of thyroid cancer. 
 
Table 6. Demographics of thyroid cancer patient samples used in statistical analysis of pIGF-
IR index  of thyroid tumor microarray (TMA) 
5. Targeting IGF-IR in thyroid cancer 
Targeted therapies consisting of human monoclonal antibodies against IGFBPs and the IGF-IR, 
or, the small molecular tyrosine kinase inhibitors (SMTKI) that target the kinase domain of 
IGF-IR, are a new class of pharmacological agents that have been shown to be useful in the 
treatment of cancers with enhanced expression and activity of IGF-IR. Pharmacological 
inhibition of IGF-I signaling with these therapeutic agents has been shown to significantly 
decrease migration, invasion, metastatic spread, and angiogenesis with little toxicity in mouse 
tumor models. Similarly, inhibition of IGF-IR signaling has also been reported to sensitize 
cancer cells to radiation and chemotherapeutic agents[48-58]. Our objective therefore, was to 
build upon this knowledge and investigate whether targeted therapy directed at the IGF-IR, 
and given in combination with chemotherapy, can be an attractive new treatment strategy for 
thyroid cancer[20]. Given our findings on up-regulation of components of the IGF-I signaling 
pathway in thyroid cancer cell lines and in human thyroid carcinoma tissue microarrays, we 
proceeded to test this hypothesis both in vitro and in vivo. 
5.1 Choice of anti-IGF-IR compounds in clinical development 
Several therapeutic agents that specifically inhibit IGF-1R but do not affect IR signaling are in 
preclinical and clinical development. Some of the strategies being used to interfere with IGF-
1R signaling (a) reduction of IGF-1R expression by antisense nucleotides (b) siRNA or 
antisense RNA against IGF-IR (c) monoclonal antibodies and (d) tyrosine kinase inhibitors. 
Altogether, 30 different IGF-1R targeting agents are in preclinical or clinical development [59-
70] (Table 3) and at least 58 active clinical trials are evaluating anti-IGF-1R targeting agents 
alone or in various combinations (www.clinicaltrials.gov). However, the two main strategies 
employed to inhibit this pathway are antibodies directed against IGF-1R or small molecule 
TKIs. Both approaches have their inherent strengths and weaknesses, particularly their 
specificity for IGF-IR and issues related to side effects like hyperglycemia. Whether sparing IR 
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is a good strategy or not is an important question to be considered as IR does play a role in 
IGF-I signaling and could compromise efficacy of anti-IGF-IR compounds. Nonetheless, we 
chose to evaluate the efficacy of A12 (a monoclonal Ab) and NVP-AEW541 (a SMTKI) in ATC 
and FTC respectively.  
5.2 In vitro effects of anti - IGF-IR antibody A12 on signal transduction, cell 
proliferation and apoptosis of thyroid cancer cell lines 
A12 is a high-affinity humanized monoclonal antibody that specifically binds to IGF-IR and 
blocks IGF-I and IGF-II signaling but does not block the binding of insulin to the insulin 
receptor. It has been shown to inhibit the growth of breast, colon, and pancreatic cancer cell 
lines, both in vitro and in subcutaneous tumors in nude mouse models by antibody-
mediated blockade of ligand binding to IGF-IR. In a study of xenograft tumor model of 
breast, pancreas and colon cancer, A12 produced a marked increase in apoptosis with 
minimal toxicity [49].  
In our studies, A12 was able to completely inhibit both IGF-I and IGF-II-induced 
phosphorylation of IGF-IR at high concentrations (100 nM) in TC cell lines (Fig 7). At lower 
concentrations (1 nM and 50 nM), it was able to inhibit the phosphorylation of IRS-I, Akt and 
MAPK. However, 10 fold more A12 was required to inhibit the IGF-2 mediated signaling (Fig. 7).  
 
Fig. 7. Dose-dependent inhibition of IGF-1- and IGF-II-induced IGF-IR┚, IRS-I, Akt, and 
MAPK autophosphorylation in ARO cells after treatment with A12. Serum-starved ARO 
cells were treated with A12 (0-100 nM) for 2 hours and then incubated with or without IGF-I 
or IGF-II (10 nM) for 10 minutes. Total protein extracts were obtained to analyze IGF-IR 
signaling components by western blotting. Note that 10 times more A12 is required to 
inhibit IGF-II signaling in ARO cells [2]. 
Twenty-four hours after plating, the cells were treated with increasing concentrations of A12 
(0-100 nM) without (A) or with (B) IGF-I stimulation for 72 hours. At the end of incubation, 
the inhibitory effect of A12 was measured using an MTT assay (Fig. 8).  
With respect to its effect on cell proliferation, increasing the concentration of A12, with or 
without IGF-I, inhibited the proliferation of some TC cell lines (ARO, DRO & C643). Other 
TC cell lines (Hth74, KAT4 and ATC-A) were only minimally responsive to A12 treatment 
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(Fig. 8). To understand if this difference was due to differential induction of apoptosis, A12 
treated cells were analyzed by Flowcytometry (FCM). Only minimal induction of apoptosis 
was observed in A12 treated cells, suggesting that growth inhibitory effects of A12 were 
driven through apoptosis independent pathways in vitro. Nonetheless, combining A12 with 
Irinotecan (chemotherapeutic drug of choice for head and neck cancers) was particularly 
useful in sensitizing ARO cells to the cytotoxic effects of Irinotecan (Fig. 9).  
 
Fig. 8. Inhibition of survival and IGF-I induced proliferation by increasing concentration of 
A12 in ATC cell lines ARO, DRO, C643, Hth74, ATC-A, and KAT4. All ATC cell lines were 
plated in 96-well plates at a density of 2000 cells/well.  
 
Fig. 9. Synergistic effect of A12 and Irinotecan on in vitro cell proliferation. ARO cells per 
well were grown in RPMI 1640 medium supplemented with 10% FBS for 24 hours. They 
were then treated with various concentrations of Irinotecan (0.01–15 mM) or with irinotecan 
with or without 5 nM A12. After a 3-day incubation period, number of metabolically active 
cells were determined with an MTT assay. Bars indicate mean values ± SE,. *P < .05 for cells 
treated with the combination versus vehicle-treated controls. 
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But, unlike Herceptin that down regulates ErbB2 receptor expression, IGF-IR expression 
remained unchanged in cells concomitantly treated with IGF-I and A12[2]. Similar findings 
have been reported for breast cancer cells[49]. 
5.3 In vivo A12 reduces tumor volume and prolongs survival in combination with 
irinotecan in an orthotopic nude mice model of ATC 
Since it is the anaplastic thyroid carcinoma that is associated with poor clinical outcome and 
some ATC cell lines showed moderate IGF-IR and pIGF-IR expression [1], preclinical 
efficacy of A12 antibody as a single agent and in combination with chemotherapy was first 
evaluated in a nude mouse model of ATC[2]. Four groups [placebo (control), A12, 
irinotecan, and A12 plus irinotecan] of 10 mice each were analyzed. Treatment with A12 or 
irinotecan alone led to a 57% and 80% decrease respectively in the tumor volumes of ARO 
xenografts. The differences in the mean tumor volume compared with the control group were 
statistically significant (P = 0.023 [for A12] and 0.002 [irinotecan], respectively). However, the 
highest growth inhibition was achieved by the co-administration of A12 plus irinotecan. At the 
end of the 3-week treatment period, mice treated with A12 plus irinotecan showed a 93% 
decrease in the estimated mean tumor volumes compared with the control group (P = 0.001). 
The decrease in mean tumor volumes in mice receiving combination treatment was also 
significantly greater than that of the groups receiving A12 or irinotecan alone (P < 0.01) (Fig. 
10A & B). A12 was well tolerated by the animals, without substantial adverse effects. The 
weights of the animals remained constant throughout the treatment period (data not shown) 
and none of the animals had to be killed before the end of the study. In the survival study, the 
survival rates of the mice treated with irinotecan alone and combination treatment was 
significantly greater than that of the mice in the control group with P values of 0.044 and 
0.0003 respectively. The combination group also achieved a greater survival rate than mice 
treated with A12 alone (P = 0.004). However, there was no significant improvement in the 
survival rates between the group treated with A12 alone and the control group (P = 0.356)  
(Fig. 10C). 
5.4 Therapeutic potential of IGF-IR specific small molecular tyrosine kinase inhibitor 
NVP-AEW541 in an orthotopic follicular thyroid carcinoma model  
Small molecular tyrosine kinase inhibitors are another class of anti-tumor agents frequently 
used to inhibit IGF-IR signaling. They inhibit both ligand independent and ligand-
dependent receptor phosphorylation and do not evoke immunogenic response on repeated 
exposure. Due to their small size, they also exhibit good tumor penetration. NVP-AEW541 
(Caymen Chemical) is one such SMTKI that is a more potent inhibitor of IGF-IR (IC50 = 
0.086 µM), eventhough, at high enough concentrations (IC50 = 2.3 µM) it can also inhibit the 
closely related insulin receptor. Structurally, NVP-AEW541 is a pyrrolo[2,3-d]pyrimidine 
derivative that can abrogate IGF-I-mediated survival and colony formation in soft agar at 
concentrations that are consistent with inhibition of IGF-IR auto-phosphorylation in vitro. In 
vivo, it has also been shown to inhibit IGF-IR signaling in tumor xenografts and significantly 
reduce the growth of IGF-IR-driven fibrosarcomas[54]. To evaluate its efficacy in thyroid 
cancer, human follicular thyroid cancer cell line stably expressing a constitutively activated 
form of IGF-IR with a downstream luciferase reporter were injected into the thyroid glands 
of 8-week-old athymic mice. We found that injection of 2.5×105 WRO cells was sufficient for  
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Fig. 10. In vivo antitumor effects of single drugs or simultaneous combination of irinotecan 
and A12 on tumor growth and survival in an orthotopic nu/nu model of ATC. ARO cells 
were injected into the right thyroid lobe of the mice. Four days after injection, the mice were 
randomized into 4 groups (10mice in each group) and the drugs were administered as 
follows: irinotecan (50 mg/kg i.p. every week) or A12 (1mg/250ul/mouse 2x weekly).  
A) After 3 weeks of treatment, all the mice were killed, and necropsy was performed. 
Representative images from each group of mice are shown to highlight the effect of drugs 
over control. B)At the end of the growth-inhibition study, the tumors were measured in 
three dimensions, and the mean tumor volumes were calculated in each group.* P = 0.023, 
compared with the control group; † P = 0.002, compared with the control group; ‡ P = 0.001, 
compared with the control group; and P < 0.01, compared with the A12-alone and 
irinotecan-alone groups (independent t-test). C, The combined treatment of A12 plus 
irinotecan prolonged the survival rate in the orthotopic nude mouse ATC model. Irinotecan 
alone or in combination with A12 significantly increased the survival rate compared with 
that of the control group (P < 0.05). 
tumor development. Tumors were visualized via non-invasive real time imaging as early as 
10 days post-implantation. After randomization into 3 separate groups with 10 mice in each 
group, they were either treated with placebo (25 mM tartaric acid solution), Irinotecan (50 
mg/kg, I.P. once a week) or NVP-AEW541 (50 mg/kg PO twice daily). Real-time whole-
body fluorescence imaging was carried out weekly to monitor tumor growth in response to 
the various treatments. After approximately three weeks, as the control group of mice 
became premorbid, mice from all the three groups were sacrificed and tumors harvested at 
necropsy. Time to premorbid condition varied between mice and was associated with 
primary tumor growth pattern (early local compression of the esophagus) rather than 
development of metastatic disease. Additionally, difficulty with oral gavage in mice with  
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Fig. 11. Realtime bioluminescent imaging (BLI) to monitor the growth of orthotopically 
inoculated FTC cells treated with placebo, Irinotecan or NVP-AEW541. A) Representative 
images of mouse at days 10, 17, and 24 after inoculation. (B) Quantification of biochemically 
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measured luciferase activity (RLU), an indicator of tumor burden to assess the effect of 
drugs on the respective days shown in panel (A). Tumor growth was significantly inhibited 
in the NVP-AEW541 treated group as compared to the placebo treated group. Median and 
range is shown for each point on the graph. Statistics were performed by Student’s t test, 
and significance (P < 0.05) relative to control is noted in the graph. 
tumors obstructing the esophagus also partially affected the outcome of survival in these 
mice. Despite the difficulties, NVP-AEW541 significantly inhibited the growth of orthotopic 
Wro tumors in nude mice (Fig. 11A) as compared to control or Irinotecan-treated mice (Fig. 
11B). Furthermore, microvessel density (MVD) was also significantly decreased after 
treatment with this compound (Fig. 12) and correlated with decreased VEGF secretion by 
vascular endothelial growth factors (VEGF) WRO cells treated with NVP-AEW541 in an in 
vitro ELISA assay (see below). These experiments were conducted only once. Pictorial data 
has been presented from a representative group of mice and quantitative analysis is based 
on data obtained from 6 – 8 mice/group. 
5.5 Both IGF-IR antibody A12 and SMTKI inhibitor NVP-AEW541 inhibit IGF-I signaling 
and tumor angiogenesis in orthotopic ATC and FTC models  
IGFs have been found to promote the growth, survival, and migration of tumor cells, as well 
as to induce the syntheses of vascular endothelial growth factors A and C and matrix 
metalloproteinase 2, which may favor the development of the blood supply essential for the 
progressive growth of primary malignancies and the development of metastases[71-73]. A 
recent study was conducted to determine whether anti IGF-IR therapy inhibits IGF-I 
signaling and tumor angiogenesis in vivo. Immunohistochemical analyses of ATC tumors 
treated with A12 or A12 and Irinotecan showed a decrease in pIGF-IR┚, pAkt, and PCNA 
staining and an increase in apoptosis in both the treatment groups in vivo[2]. These 
observations were in striking contrast to A12’s effect in vitro, where treatment of ATC cell 
lines with A12 failed to induce an apoptotic response. A possible explanation for this 
discordance could be that A12’s additional ability to induce antibody-dependent cell 
cytotoxicity (ADCC) and complement-mediated cell death (CDC) in vivo results in the 
activation of immune response and inhibition of tumor growth. Strangely enough, despite 
A12’s ability to induce apoptosis in vivo, the survival rate of mice treated with A12 alone 
was not improved over that of the placebo-treated mice (p=0.578). Contrarily, mice in the 
combination treatment group showed significant survival advantage (p=0.002) over the 
mice in control group[2]. These observations suggest that anti-IGF-IR therapy when given 
in combination with other therapeutic strategies augments anti-tumor effects. To further 
determine if anti-IGF-IR therapies can be used to inhibit thyroid tumor angiogenesis, we 
sought to determine whether IGF-IR regulates any molecular targets of angiogenesis as 
has been reported for colorectal cancer cells[74]. In these studies, stimulation of IGF-IR in 
colorectal cells has been shown to induce the expression of VEGF to regulate development 
of new blood vessels[75]. Furthermore, blockade of IGF-IR led to significant down-
regulation of VEGF and inhibition of tumor growth and lymph node metastasis of these 
tumors[76]. To test whether over-expression of IGF-IR in follicular carcinoma cells (WRO) 
increases VEGF secretion as reported for the colon carcinoma cells, 5x105 vector 
transfected (WRO-puro) or wild type IGF-IR over-expressing (WRO-wt) or constitutively 
active IGF-IR expressing (CA-IGF-IR) WRO cells were allowed to attach and grow for  
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Fig. 12. Histological analysis of tumor sections from Wro-Cd8IGF-IR orthotopic tumors 
untreated or treated with NVP-AEW541. Tumor samples from representative animals were 
resected, fixed, and processed for immunohistochemistry with anti CD31 antibody. NVP-
AEW541-treated samples showed noticeable reduction in angiogenesis compared to control. 
Magnification 200X. 
24hrs. The supernatant was then replaced with 2 - 3 mL fresh 2% heat-inactivated fetal 
bovine serum containing culture medium and further cultured for 24 hours. The 
concentration of VEGF165 in each supernatant was determined using commercially 
available enzyme-linked immune-absorbent assay (ELISA) kit (R&D Systems, Minneapolis, 
MN). Culture supernatant from MDA1986 cells was used as positive control for VEGF-A 
secretion. Both the IGF-IR overexpressing WRO cells and the CA-IGF-IR cells secreted 
significantly higher levels of VEGF-A as compared to the vector control cells (WRO Puro). 
We further observed that the treatment of these cells with the SMTKI NVP-AEW541 
partially suppressed IGF-IR induced up-regulation of VEGF secretion (Fig. 13; P < 0.005 in 
both cases), suggesting that VEGF secretion in part may be regulated through the IGF-IR 
signaling pathway.  
However, even though NVP-AEW541 is highly sensitive to IGF-IR, it does demonstrate 
inhibitory activity towards IR, MAPK and PI3K. Thus involvement of other TKIs in the 
process cannot be overruled. Nonetheless these data does provide credence to our 
hypothesis that thyroid tumor angiogenesis may be the result of enhanced VEGF secretion 
in IGF-IR over-expressing tumors. Additional evidence for involvement of IGF-IR in thyroid 
tumor angiogenesis came from our observations in A12 treated orthotopic ATC specimens. 
Staining of these tumors for CD31 showed a significant decrease in microvessel density 
especially in tumors treated with A12 alone and in tumors treated in combination with 
Irinotecan. Additional staining for pIGF-IR in the tumor endothelium of these tumors 
confirmed that this response was due to the loss of phosphorylation of IGF-IR in tumor-
associated endothelium of A12-treated tumors[2]. In summary, these studies suggest that 
thyroid tumor angiogenesis is partially regulated through IGF-IR signaling in both ATCs 
and FTC orthotopic xenografts. To further confirm if human thyroid specimens showed a 
correlation between IGF-IR signaling and local metastasis, we measured the pIGF-IR content 
of human thyroid cancer specimens with and without lymph node metastasis. We observed 
that pIGF-IR expression when computed as an index (pIGF-IR index) varied amongst 
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thyroid tumors. Particularly, pIGF-IR index of thyroid tumors with lymph node metastasis 
was lower than for ones without lymph node metastasis, suggesting a direct role for IGF-I 
signaling in local thyroid tumor metastasis.  
 
Fig. 13. Effect of NVP-AEW541 on VEGF - A secretion by follicular thyroid carcinoma cells 
that over express either the wt-IGF-IR or the constitutively activated IGF-IR or are vector 
transfected (Wro-puro). 5x105 cells/ml were allowed to attach and grow for 24hrs in 6 well 
dishes. The supernatant was then replaced with 2 mL fresh culture medium containing  
2% heat-inactivated fetal bovine serum and further cultured for 24 hours in the presence of  
IGF-IR inhibitor NVP-AEW541. The dose of NVP-AEW541 was predetermined using a 
standard MTT assay and was found to bring about 50% inhibition in cell growth at a 
concentration of 0.2uM. VEGF secretion was evaluated by ELISA in conditioned medium of 
the wro clones 24 hrs after exposing to the drug using commercially available enzyme-
linked immuno-absorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN). Results are 
presented in pg VEGF165 /106 cells/24h for control and treated samples as mean ± STE 
from three separate experiments. MDA1986 cells were used as positive control for  
VEGF-A secretion. VEGF165 was undetectable in media without the cells  
(data for controls not shown) 
6. Conclusions 
IGF-I/IGF-IR axis plays a pivotal role in thyroid tumor progression, particularly by 
enhancing the angiogenic response of these tumors. Thus targeting IGF-1R signaling 
particularly in FTC, PTC and more differentiated ATCs could have significant therapeutic 
potential. Many compounds that directly target IGF-1R have now been developed and the 
two most investigated strategies to date have used IGF-1R tyrosine kinase inhibitors such as 
NVP-AEW541 and anti-IGF-1R monoclonal antibodies such as A12. We tested the specificity 
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of both these compounds in orthotopic models of ATC and FTC and have presented data 
that shows their efficacy. Furthermore, blockade of IGF-IR suppressed IGF-I signaling, 
induced apoptosis in vitro and in vivo. Both compounds also suppressed angiogenesis 
although via different mechanisms. Combining A12 treatment with standard of care 
chemotherapeutic drug Irinotecan enhanced the cytotoxic effects of the chemotherapeutic 
drug. Our results are in agreement with previously reported data in other solid tumors and 
suggest that blocking IGF-IR with A12 or NVP-AEW541 seems to be a potential avenue for 
treating thyroid cancer through their direct antitumor effects and their effects on tumor 
vasculature. Additionally, we reviewed additional strategies that are under clinical 
development or in clinical trial for targeting this axis in cancer. Nevertheless, as clinical 
developmental programs progress careful attention must be paid to the potential side effects 
of this approach, especially since IGF-I signaling plays an equally important role in cell 
growth, energy metabolism and differentiation. A closer look on the effect of dose and 
schedule on toxicity are also warranted.  
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